4 completed, 2 recruiting, 1 available. 1 Early Phase 1, 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Pemphigus, Benign Familial: new trials by email Literature Review of Pemphigus, Benign Familial trials Research Report on Pemphigus, Benign Familial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease KB111 - Hailey Hailey Disease, Skin Diseases | Early Phase 1 | Recruiting | Krystal Biotech, Inc. | 7 | 2026-05-06 | 2026-07-21 |
| Efficacy of Guselkumab in Treating Hailey Hailey Disease Guselkumab - Hailey Hailey Disease | Phase 2 | Recruiting | Yale University | 10 | 2025-03-13 | 2026-06-22 |
| Skin Microbiome Profile in Hailey-Hailey Disease Doxycycline - Hailey-Hailey Disease | Completed | Gangnam Severance Hospital | 18 | 2020-05-08 | 2021-08-16 | |
| M. Hailey-Hailey: hSPCA1 Expression and Skin Structure Upon Laser Therapy Skin biopsy - Hailey Hailey Disease | Not applicable | Completed | Maastricht University Medical Center | 11 | 2018-12-21 | 2024-03-20 |
| Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Botulism Toxin Treatment - Hailey-Hailey Disease, Darier Disease | Phase 1 | Completed | University Hospital, Toulouse | 30 | 2015-09-01 | 2026-09-21 |
| National Registry for Ichthyosis and Related Disorders Darier Disease, Hailey-Hailey Disease | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 610 | 1994-09-01 | 2022-09-28 | |
| Compassionate Use or Expanded Access of Dupilumab Dupilumab - Type 2 Inflammatory Disorders | Available | Regeneron Pharmaceuticals | 2026-09-01 |
Darier Disease (2) · Actinic Prurigo (1) · Chronic Urticaria (1) · Dermatitis, Exfoliative (1) · Eosinophilic Esophagitis (1) · Epidermal Nevus (1) · Hyperkeratosis, Epidermolytic (1) · Hypersensitivity (1) · Ichthyosiform Erythroderma, Congenital (1) · Ichthyosis (1) · Ichthyosis, Lamellar (1) · Ichthyosis, X-Linked (1) · Keratosis (1) · Nails, Malformed (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Skin Diseases, Genetic (7) · Skin Diseases, Vesiculobullous (7) · Skin and Connective Tissue Diseases (7) · Skin Diseases (6) · Pathological Conditions, Signs and Symptoms (2) · Autoimmune Diseases (1) · Chronic Disease (1) · Congenital Abnormalities (1) · Conjunctival Diseases (1) · Dermatitis (1) · Digestive System Diseases (1) · Disease Attributes (1) · Eosinophilia (1)
Doxycycline (1) · dupilumab (1) · guselkumab (1)
Gangnam Severance Hospital (1) · Krystal Biotech, Inc. (1) · Maastricht University Medical Center (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Regeneron Pharmaceuticals (1) · University Hospital, Toulouse (1) · Yale University (1)
United States (3) · France (1) · Netherlands (1) · South Korea (1)
Keith Choate, MD, PhD (1) · Philip Fleckman, MD (1) · Sang Eun Lee (1) · Valerie Verstraeten, MD PhD (1)
PMID 11511292, PMID 11912510, PMID 12648223, PMID 14734878, PMID 15238912, PMID 16250204, PMID 18571597, PMID 18948357, PMID 19241467, PMID 33602313, PMID 9804339, PMID 9843209